

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
28 November 2024 (28.11.2024)



(10) International Publication Number  
**WO 2024/243023 A1**

(51) International Patent Classification:

A61K 31/38 (2006.01) A61K 31/7028 (2006.01)  
A61K 31/70 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/029906

(22) International Filing Date:

17 May 2024 (17.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/467,823 19 May 2023 (19.05.2023) US

(71) Applicant: MIRUM PHARMACEUTICALS, INC.  
[US/US]; 989 E Hillsdale Blvd., Suite 300, Foster City, CA  
94404 (US).

(72) Inventor: VED, Parag; c/o Mirum Pharmaceuticals, Inc.,  
989 E Hillsdale Blvd., Suite 300, Foster City, CA 94404  
(US).

(74) Agent: JIN, Regina et al.; Troutman Pepper Hamilton San-  
ders LLP, 875 Third Avenue, New York, NY 10022 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,4,5-TETRAHYDRO-BENZOTHIEPIN-1,1-DIOXIDE  
DERIVATIVES AND THE USE THEREOF




FIG. 1

(57) Abstract: Provided herein are solid dosage forms comprising 2,3,4,5-tetrahydro-benzothiepin-1,1-dioxide derivatives, for example volixibat or a pharmaceutically acceptable salt thereof. Also provided herein are embodiments directed to methods of treating cholestatic liver disease, hyperlipidemia, arteriosclerosis, or Syndrome X, or lowering the serum cholesterol level in a subject in need thereof, wherein the methods comprise administering to the subject a therapeutically effective amount of the solid dosage form of the pharmaceutical composition comprising volixibat.

WO 2024/243023 A1